SpectraCure (SPEC.ST) Stock Analysis & AI Equity Report
SpectraCure (SPEC.ST) overview
SpectraCure (SPEC.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, SpectraCure reported revenue of SEK 0m and operating profit of SEK -54.4m; the year-end share price was 0.16 SEK and market capitalisation was SEK 63.8m. SpectraCure is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get SpectraCure's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About SpectraCure
SpectraCure AB is a Swedish medical technology company based in Lund that develops and commercialises Q-PRO, a treatment system for prostate cancer based on photodynamic therapy. The platform combines a laser device, dose-planning software and disposable components. The company is conducting clinical studies in recurrent and primary localised prostate cancer in North America and Europe.
Generate the SpectraCure report
SpectraCure is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for SpectraCure and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.